High-Dose Insulin with Dextrose for Cardiogenic Shock
For toxin-induced cardiogenic shock (particularly from calcium channel blockers or beta-blockers), administer high-dose insulin starting with a 1 unit/kg bolus followed by 1 unit/kg/hour infusion, with concurrent dextrose supplementation to maintain euglycemia; however, this therapy has NO role in non-toxin-induced cardiogenic shock or vasoplegic shock where it may worsen outcomes. 1
Critical Context: When to Use vs. Avoid
High-dose insulin is not an antidote but an inodilator with a 15-60 minute onset of action, making it second-line therapy even in appropriate cases 1. The distinction between toxin-induced and other forms of cardiogenic shock is paramount:
Appropriate Use: Toxin-Induced Cardiogenic Shock
- Primary indications: Calcium channel blocker and beta-blocker overdoses causing cardiogenic shock 2, 3
- Mechanism: Provides inotropic support through enhanced glucose uptake into cardiac myocytes and peripheral vasodilation 3
- Documented success with doses ranging from 1-20 units/kg/hour 4, 2
Contraindicated: Vasoplegic Shock
- Do not use in isolated vasoplegic shock (e.g., dihydropyridine calcium channel blocker overdose) where insulin-induced vasodilation will exacerbate hypotension 1
- Requires concurrent norepinephrine to counteract vasodilatory effects 1
Administration Protocol
Initial Dosing
- Insulin bolus: 1 unit/kg regular insulin IV 3
- Dextrose bolus: 25 grams IV (50 mL of 50% dextrose) 3
- Insulin infusion: Start at 1 unit/kg/hour 3
Dose Escalation
- Animal studies demonstrate dose-response relationship with cardiac output improvement up to 10 units/kg/hour 2
- Case reports document safe escalation to 20 units/kg/hour (highest published dose) over 32 hours 4
- Titrate based on hemodynamic response, not to a predetermined ceiling
Dextrose Management
Critical: Dextrose administration must be titrated to prevent both hypoglycemia and excessive hyperglycemia.
- For hypoglycemia treatment: Administer 10-20 grams IV dextrose (NOT the traditional 25-50 grams) 5
- Preferred method: 10% dextrose in 50 mL (5-gram) aliquots repeated every minute until symptoms resolve 5
- Avoid: Rapid administration of 50% dextrose, which causes excessive BG elevation and has been associated with cardiac arrest and hyperkalemia 5
- Maximum safe infusion rate: 0.5 g/kg/hour for peripheral administration; 0.8 g/kg/hour retains 95% of dextrose 6
Monitoring Requirements
Glucose Monitoring
- Frequency: Every 1-2 hours during insulin infusion 5
- Target: Maintain euglycemia (avoid both hypoglycemia and hyperglycemia >180 mg/dL)
- Every 4-hour testing produces hypoglycemia rates >10% and is inadequate 5
Electrolyte Monitoring
- Potassium: Check frequently; hypokalemia is predictable and can persist beyond insulin cessation 1
- Hypoglycemia and hypokalemia are the primary adverse effects requiring vigilant monitoring 4, 1
Hemodynamic Monitoring
- Expect 15-60 minute delay before hemodynamic improvement 1
- In successful cases, documented improvement from LVEF 10-15% to 50-55% within 3.5 hours 7
Concurrent Vasopressor Support
Mandatory: Use norepinephrine concurrently to counteract insulin-induced vasodilation 1. High-dose insulin should never be used as monotherapy for cardiogenic shock.
Common Pitfalls
- Using in wrong shock type: Insulin worsens vasoplegic shock; only use for cardiogenic shock from toxins 1
- Inadequate glucose monitoring: Every 4-hour checks are insufficient 5
- Excessive dextrose boluses: Traditional 50-gram doses cause rebound hyperglycemia; use 10-20 grams 5
- Expecting immediate effect: Onset takes 15-60 minutes, unlike catecholamines 1
- Ignoring potassium: Hypokalemia develops predictably and requires replacement 1
Evidence Quality Note
While animal studies show clear dose-response relationships 2 and case series demonstrate survival in otherwise fatal overdoses 8, 3, no randomized controlled trials exist for high-dose insulin in human cardiogenic shock. The evidence base consists of animal models and case reports/series. Recent expert recommendations for cardiogenic shock management do not include high-dose insulin for non-toxin etiologies 9.